Clinical trials
Phase 3 Asthma trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 4 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 6 |
| 2013 | 6 |
| 2014 | 8 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 5 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 55 |
| Terminated | 8 |
| Recruiting | 7 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 20 |
| GlaxoSmithKline | 18 |
| Novartis Pharmaceuticals | 5 |
| Areteia Therapeutics | 4 |
| Chiesi Farmaceutici S.p.A. | 4 |
| Hoffmann-La Roche | 4 |
| Boehringer Ingelheim | 3 |
| Sanofi | 3 |
| Mundipharma Research Limited | 2 |
| Teva Branded Pharmaceutical Products R&D, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asthma | 75 |
| Pulmonary Eosinophilia | 8 |
| Bronchial Diseases | 6 |
| Respiratory Tract Diseases | 6 |
| Lung Diseases | 5 |
| Lung Diseases, Obstructive | 5 |
| Dyspnea | 2 |
| Hypersensitivity | 2 |
| Immune System Diseases | 2 |
| Pulmonary Disease, Chronic Obstructive | 2 |
Trials
Showing 1 to 25 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.